Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Scienture Holdings's pretax income for the
three
months ended in Jun. 2026 was $-2.82 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was $-39.95 Mil.
Scienture Holdings's pretax margin was -820.35%.
During the past 13 years, Scienture Holdings's highest Pretax Margin was 9.86%. The lowest was -13707.30%. And the median was -35.35%.
During the past 13 years, Scienture Holdings's highest Pretax Margin was 9.86%. The lowest was -13707.30%. And the median was -35.35%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scienture Holdings Pre-Tax Income Related Terms
Scienture Holdings Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Scienture Holdings's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCNX vs PMHS, HEWA, BLMH: Pre-Tax Income Comparison
For the Pharmaceutical Retailers subindustry, Scienture Holdings's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scienture Holdings Pre-Tax Income vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Scienture Holdings's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Scienture Holdings's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scienture Holdings (SCNX) has a Pre-Tax Income of $-39.95 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Scienture Holdings and its competitors.
Is Scienture Holdings' Pre-Tax Income too high?
Scienture Holdings' current Pre-Tax Income is $-39.95 Mil. Overall, Scienture Holdings has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Scienture Holdings' Pre-Tax Income compare to PMHS and HEWA?
Scienture Holdings' Pre-Tax Income of $-39.95 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Healthcare Providers & Services company?
A good Pre-Tax Income depends on the Healthcare Providers & Services industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Scienture Holdings and its competitors. Scienture Holdings's current Pre-Tax Income is $-39.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scienture Holdings stock overvalued right now?
Based on GuruFocus' analysis, Scienture Holdings (SCNX) is currently considered Possible Value Trap. The stock's GF Value™ is $0.51, compared to a current price of $0.35 — trading 31.7% below its estimated fair value. The current Pre-Tax Income is $-39.95 Mil. Scienture Holdings' overall GF Score™ is 43/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Scienture Holdings (SCNX), the current Pre-Tax Income is $-39.95 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scienture Holdings (SCNX) Overvalued in 2026?
Based on GuruFocus' analysis, Scienture Holdings stock appears to be undervalued.
The current stock price of $0.35 is trading 31.7% below its estimated GF Value™ of $0.51.
GuruFocus considers Scienture Holdings to be Possible Value Trap.
Key valuation signals for SCNX:
Pre-Tax Income: $-39.95 Mil
GF Value™: $0.51 vs. price of $0.35 (31.7% below fair value)
No single metric tells the full story. See the SCNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
43GF Score
Get the complete analysis for SCNX
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNX has been successfully added to your 
